Insys Therapeutics weakness a buying opportunity, says JMP Securities JMP Securities said Insys Therapeutics (INSY) is weak on concerns that Subsys may be added to Express Scripts' (ESRX) exclusion list in 2015. The analyst does not know if it will or not be added but said the potential impact would not be material to sales or growth because the product is not included in any PBM preferred formula positions and has prior authorization requirements. The analyst would use weakness as a buying opportunity and reiterates its Outperform rating and $65 price target.
Insys Therapeutics to initiate five Phase III trials in FY15 Insys Therapeutics announced progress and expected milestones for multiple projects in its pipeline of innovative supportive care and therapy products and candidates. The company intends to submit a New Drug Application to the FDA and to advance five programs into Phase III clinical trials in 2015.